vs
COPT DEFENSE PROPERTIES（CDP）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是COPT DEFENSE PROPERTIES的1.1倍（$207.3M vs $197.4M），COPT DEFENSE PROPERTIES净利率更高（20.0% vs -62.0%，领先82.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 7.6%），COPT DEFENSE PROPERTIES自由现金流更多（$288.9M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 1.1%）
COPT Defense Properties是一家专业房地产投资信托基金，重点投资写字楼物业，资产主要布局于华盛顿大都会区的近郊区域，核心租户为美国政府及国防军工行业企业。截至2024年12月31日，公司旗下共持有164栋写字楼，总面积达1650万平方英尺，同时运营31个单租户数据中心，总面积590万平方英尺。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CDP vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $197.4M | $207.3M |
| 净利润 | $39.4M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 19.9% | -54.7% |
| 净利率 | 20.0% | -62.0% |
| 营收同比 | 7.6% | 25.9% |
| 净利润同比 | 8.0% | 3.5% |
| 每股收益（稀释后） | $0.32 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $197.4M | $207.3M | ||
| Q3 25 | $188.8M | $159.9M | ||
| Q2 25 | $189.9M | $166.5M | ||
| Q1 25 | $187.9M | $139.3M | ||
| Q4 24 | $183.4M | $164.6M | ||
| Q3 24 | $189.2M | $139.5M | ||
| Q2 24 | $187.3M | $147.0M | ||
| Q1 24 | $193.3M | $108.8M |
| Q4 25 | $39.4M | $-128.6M | ||
| Q3 25 | $43.7M | $-180.4M | ||
| Q2 25 | $40.2M | $-115.0M | ||
| Q1 25 | $36.2M | $-151.1M | ||
| Q4 24 | $36.5M | $-133.2M | ||
| Q3 24 | $37.4M | $-133.5M | ||
| Q2 24 | $36.4M | $-131.6M | ||
| Q1 24 | $33.7M | $-170.7M |
| Q4 25 | 19.9% | -54.7% | ||
| Q3 25 | 22.5% | -106.9% | ||
| Q2 25 | 21.0% | -64.8% | ||
| Q1 25 | 19.1% | -102.6% | ||
| Q4 24 | 19.7% | -74.3% | ||
| Q3 24 | 19.8% | -94.6% | ||
| Q2 24 | 19.4% | -79.1% | ||
| Q1 24 | 17.5% | -151.9% |
| Q4 25 | 20.0% | -62.0% | ||
| Q3 25 | 23.2% | -112.8% | ||
| Q2 25 | 21.1% | -69.0% | ||
| Q1 25 | 19.3% | -108.5% | ||
| Q4 24 | 19.9% | -80.9% | ||
| Q3 24 | 19.8% | -95.7% | ||
| Q2 24 | 19.4% | -89.5% | ||
| Q1 24 | 17.4% | -156.8% |
| Q4 25 | $0.32 | $-1.28 | ||
| Q3 25 | $0.37 | $-1.81 | ||
| Q2 25 | $0.34 | $-1.17 | ||
| Q1 25 | $0.31 | $-1.57 | ||
| Q4 24 | $0.31 | $-1.34 | ||
| Q3 24 | $0.32 | $-1.40 | ||
| Q2 24 | $0.31 | $-1.52 | ||
| Q1 24 | $0.29 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $275.0M | $421.0M |
| 总债务越低越好 | $2.8B | — |
| 股东权益账面价值 | $1.5B | $-80.0M |
| 总资产 | $4.7B | $1.5B |
| 负债/权益比越低杠杆越低 | 1.83× | — |
8季度趋势，按日历期对齐
| Q4 25 | $275.0M | $421.0M | ||
| Q3 25 | $23.7M | $202.5M | ||
| Q2 25 | $21.3M | $176.3M | ||
| Q1 25 | $24.3M | $127.1M | ||
| Q4 24 | $38.3M | $174.0M | ||
| Q3 24 | $34.5M | $150.6M | ||
| Q2 24 | $100.4M | $480.7M | ||
| Q1 24 | $123.1M | $112.3M |
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
| Q4 25 | $1.5B | $-80.0M | ||
| Q3 25 | $1.5B | $9.2M | ||
| Q2 25 | $1.5B | $151.3M | ||
| Q1 25 | $1.5B | $144.2M | ||
| Q4 24 | $1.5B | $255.0M | ||
| Q3 24 | $1.5B | $346.8M | ||
| Q2 24 | $1.5B | $432.4M | ||
| Q1 24 | $1.5B | $140.3M |
| Q4 25 | $4.7B | $1.5B | ||
| Q3 25 | $4.4B | $1.2B | ||
| Q2 25 | $4.3B | $1.3B | ||
| Q1 25 | $4.3B | $1.3B | ||
| Q4 24 | $4.3B | $1.5B | ||
| Q3 24 | $4.2B | $1.5B | ||
| Q2 24 | $4.2B | $1.6B | ||
| Q1 24 | $4.2B | $1.3B |
| Q4 25 | 1.83× | — | ||
| Q3 25 | 1.62× | — | ||
| Q2 25 | 1.63× | — | ||
| Q1 25 | 1.62× | — | ||
| Q4 24 | 1.60× | — | ||
| Q3 24 | 1.61× | — | ||
| Q2 24 | 1.61× | — | ||
| Q1 24 | 1.63× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $309.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $288.9M | $-100.8M |
| 自由现金流率自由现金流/营收 | 146.4% | -48.6% |
| 资本支出强度资本支出/营收 | 10.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 7.87× | — |
| 过去12个月自由现金流最近4个季度 | $501.5M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $309.9M | $-99.8M | ||
| Q3 25 | $68.6M | $-91.4M | ||
| Q2 25 | $87.9M | $-108.3M | ||
| Q1 25 | $72.1M | $-166.5M | ||
| Q4 24 | $331.0M | $-79.3M | ||
| Q3 24 | $65.1M | $-67.0M | ||
| Q2 24 | $93.8M | $-77.0M | ||
| Q1 24 | $71.0M | $-190.7M |
| Q4 25 | $288.9M | $-100.8M | ||
| Q3 25 | $62.9M | $-92.7M | ||
| Q2 25 | $84.5M | $-110.7M | ||
| Q1 25 | $65.1M | $-167.8M | ||
| Q4 24 | $299.6M | $-79.5M | ||
| Q3 24 | $61.0M | $-68.6M | ||
| Q2 24 | $88.4M | $-79.0M | ||
| Q1 24 | $57.9M | $-193.9M |
| Q4 25 | 146.4% | -48.6% | ||
| Q3 25 | 33.3% | -58.0% | ||
| Q2 25 | 44.5% | -66.5% | ||
| Q1 25 | 34.7% | -120.5% | ||
| Q4 24 | 163.3% | -48.3% | ||
| Q3 24 | 32.3% | -49.2% | ||
| Q2 24 | 47.2% | -53.7% | ||
| Q1 24 | 30.0% | -178.2% |
| Q4 25 | 10.7% | 0.5% | ||
| Q3 25 | 3.0% | 0.8% | ||
| Q2 25 | 1.8% | 1.5% | ||
| Q1 25 | 3.7% | 1.0% | ||
| Q4 24 | 17.1% | 0.1% | ||
| Q3 24 | 2.1% | 1.2% | ||
| Q2 24 | 2.9% | 1.4% | ||
| Q1 24 | 6.8% | 3.0% |
| Q4 25 | 7.87× | — | ||
| Q3 25 | 1.57× | — | ||
| Q2 25 | 2.19× | — | ||
| Q1 25 | 1.99× | — | ||
| Q4 24 | 9.08× | — | ||
| Q3 24 | 1.74× | — | ||
| Q2 24 | 2.58× | — | ||
| Q1 24 | 2.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDP
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
